In-licensing deal between VolitionRx and UK-based Innova Biosciences helps drive development of novel cancer diagnostics
Oxford, UK, July 24, 2013 – VolitionRx Limited (OTC: VNRX), a life sciences company focused on the development of blood-based diagnostic tests, has signed a non-exclusive in-licensing agreement with Innova Biosciences, a specialist provider of bioconjugation systems, based in Cambridge, UK. Under the agreement, Innova Biosciences will supply its Lightning-Link® Biotin technology for Volition’s NuQ® epigenetic profiling research kits. The addition of the Lightning-Link technology will help Volition to improve the accuracy of its test, whilst speeding up production of the research kits.
Volition will use Lightning-Link® for biotinylation of antibodies employed in its range of NuQ® ELISA kits available to researchers working in the fields of epigenetics and nucleosome research. Volition is also employing the Lightning-Link technology for development of Nucleosomics®-based clinical tests, including its first blood-based diagnostic test for colorectal cancer. The high yield and enhanced specificity offered by the Lightning-Link® system coupled with simplicity of use provide a significant advantage in the manufacture of Volition’s research and clinical assays.
Cancer diagnosis often requires a series of time consuming tests, with a diagnosis sometimes being made days after specimen removal. This in-licensing deal will assist the company in their development and manufacture of novel, easy to use diagnostic kits.
Dr Jake Micallef, CSO of VolitionRx, says: “We’ve been really impressed with Innova’s products. Their biotin kit is simple to use and proved more durable than many competitors’ kits, and we’ve seen significant improvements in reproducibility since we started to use them regularly. We’re looking forward to continuing to work with the Lightning-Link technology.”
Dr Andy Lane, Executive Director at Innova Biosciences, said, “This deal is another perfect example of how Lightning-Link® is increasingly being used by innovative diagnostic companies like VolitionRx to both maximise R&D output and to simplify the manufacturing process.”
Innova Biosciences invites anyone with an interest in biotinylation to view their website – http://www.innovabiosciences.com/antibody-labeling-kits/biotin-streptavidin/lightning-link-biotin.html
Company and Media Contact
Charlotte McCubbin
Singapore (m): +65 92301938
Email: c.mccubbin@volitionrx.com
Investor Relations Contact: MZ Group
Mark A. McPartland, Senior Vice President
Phone: +1-212-301-7130
Email: markmcp@mzgroup.us
Web: www.mzgroup.us
About VolitionRx:
VolitionRx is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats. VolitionRx’s development activities are currently centered in Belgium with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.
You can find more information about VolitionRX at our website at www.volitionrx.com, on Twitter at http://www.twitter.com/VolitionRx , LinkedIn at www.linkedin.com/company/1364072?trk=tyah or Facebook at www.facebook.com/volitionrx.
About Innova Biosciences Limited:
Innova Biosciences is a growing, dynamic, ISO 9001:2008 business based in Cambridge, UK. At the core of Innova’s business are the Lightning-Link®, InnovaCoat® and Thunder-Link® technologies, which simplify the production of antibody-based reagents. The expanding portfolio is sold to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide. For more information, please see www.innovabiosciences.com.
Safe Harbor Statement
Statements in this press release may be “forward-looking statements”. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission.
Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St, Stamford
Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com
